REDWOOD CITY, Calif.–(BUSINESS WIRE)– Pulmonx, leider in interventionele longgeneeskunde, heeft vandaag een tablet versie van zijn Chartis Pulmonary Assessment System, een diagnose tool ontwikkeld om geschikte patiënten voor Zephyr® Endobronchial Valve (EBV) therapie te identificeren. De Chartis Tablet is draagbaar, heeft een kleine footprint en is ontworpen om artsen van gemak te dienen tijdens pre-procedurele evaluaties. De nieuwe tablet zal worden getoond tijdens de European Respiratory Society International Congress (ERS) deze week in Amsterdam. Hij zal ook met onmiddellijke ingang commercieel beschikbaar worden in Europa, waar Zephyr EBV en Chartis Systems het CE keurmerk hebben.
Pulmonx Launches Chartis Tablet, Simplifying Patient Selection for Zephyr® Endobronchial Valve Therapy
REDWOOD CITY, Calif.–(BUSINESS WIRE)– Pulmonx®, a leader in interventional pulmonology, today announced the launch of a tablet version of its Chartis Pulmonary Assessment System, a diagnostic tool designed to identify optimal patients for Zephyr® Endobronchial Valve (EBV) therapy. The Chartis Tablet is portable, has a small footprint and is designed to be easier for physicians to use during pre-procedural evaluation. The new tablet will be showcased at the European Respiratory Society International Congress (ERS) this week in Amsterdam. It will also be commercially available immediately in Europe, where the Zephyr EBV and Chartis System have received the CE Mark.
The Chartis System is a proprietary endoscopic, catheter-based diagnostic system that identifies collateral ventilation by enabling precise and real-time assessment of flow and pressure readings for specific lobes in the lungs. This critical information allows physicians to select those patients with no or low collateral ventilation for Zephyr EBV treatment, and helps them predict with high accuracy those patients that are most likely to benefit from the therapy. Multiple randomized controlled trials have demonstrated that patients selected using the Chartis System and treated with the Zephyr EBV have experienced statistically significant improvements in lung function, exercise capacity and quality of life.
More than 65 percent of severe emphysema patients have been shown to have low collateral ventilation in one or more target lobes of the lung, demonstrating a large potential market for the Zephyr EBV treatment. The Zephyr EBV is a tiny, one-way valve placed in the lungs to block airflow to diseased regions in order to achieve lung volume reduction. Zephyr EBVs have been implanted globally in more than 10,000 patients.
With Chartis capabilities in a tablet, physicians can now place the system in a convenient location that allows them to visually focus on the procedure, ensuring the diagnostic is run as intended and that patient selection for the EBV procedure is as accurate as possible. The tablet has a high resolution touch screen and is Bluetooth-enabled for ease of use. It also includes an HDMI-out that enables picture-in-picture capabilities. The Chartis assessment can be performed during spontaneous breathing or mechanical ventilation (including jet ventilation) under general anesthesia.
“Chartis has proven remarkably effective at identifying those patients that will receive the most benefit from the Zephyr valve,” said Pulmonx Chief Executive Officer Glen French. “With our new Chartis system, we are making the diagnostic easier for physicians to use to ensure the best possible patient selection.”
Based in Redwood City, California, and Neuchâtel, Switzerland, Pulmonx is an interventional pulmonology company focused on developing life-changing, cost-effective technologies that improve the lives of patients suffering from lung disease worldwide. For more information, visit www.pulmonx.com.
The Zephyr ® EBV is an investigational device in the United States. Limited by U.S. law to investigational use.
Michelle McAdam, 310-902-1274